Circling the Wagons
Executive SummaryWhither Japan Pharma? If the last quarter's dealmaking is any hint, it's sticking pretty close to home--indeed, circling the wagons. An industry that needs to become less conservative is doing just the opposite as cost pressures increase in its home market.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.